Immune checkpoint inhibitor–associated nephritis—treatment standard
Nephrology Dialysis Transplantation · 30.10.2024 · 39 (11) · 1785-1798
DOI: 10.1093/ndt/gfae184 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 13.08.2024. Verfasst von Elena-Bianca Barbir und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: Intramural Career Development, CCaTS.
Abstract (Originalsprache)
Over the last 13 years, the use of immune checkpoint inhibitor (ICI) therapy has grown remarkably, owing to their unprecedented anti-tumor efficacy in certain tumor groups. With increased use of ICIs, we are seeing immune-related adverse events (irAEs) more frequently. Renal irAEs, such as ICI-associated acute kidney injury (ICI-AKI), are reported in 2%–5% of patients treated with ICIs, with acute tubulointerstitial nephritis (ATIN) as the most common histopathologic lesion, though various forms of glomerulonephritis have also been reported. Modifiable risk factors for ICI-AKI include concurrent use of ATIN-associated drugs, like proton pump inhibitors, non-steroidal anti-inflammatory drugs and antibiotics, and dual ICI therapy with both Cytotoxic T-lymphocyte Associated Protein 4 (CTLA-4) and Programmed Cell Death Protein 1 and its ligand (PD1/PDL-1) blockade. Kidney biopsies remain the diagnostic modality of choice, though several promising non-invasive biomarkers, which have not yet been broadly clinically validated have emerged. The treatment of ICI-AKI involves holding ICIs, discontinuation of ATIN-associated drugs and initiation of immunosuppression with corticosteroids as first-line therapy. With prompt treatment initiation, most patients achieve full or partial renal recovery, allowing for re-challenge with ICI. However, a subset of patients will require additional steroid-sparing therapies for corticosteroid-dependent or refractory ICI-AKI. Here we review developments in our understanding of the pathophysiology of ICI-AKI, the approach to diagnosis (with a focus on the emergence of novel diagnostic tools), prognostic factors and the current evidence for establishing treatment standards for ICI-AKI. As the evidence base remains largely retrospective, we identify questions that would benefit from future prospective studies in the diagnosis, management and prognostication of ICI-AKI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
- Department of Medicine, Division of Nephrology, University Health Network, University of Toronto, Toronto, ON, Canada.
ORCID-Profile: Elena-Bianca Barbir, Abhijat Kitchlu, Sandra M Herrmann
Förderung
- Intramural Career Development
- CCaTS
Zitieren
APA
Barbir, E. B., Kitchlu, A., & Herrmann, S. M. (2024). Immune checkpoint inhibitor–associated nephritis—treatment standard. Nephrology Dialysis Transplantation, 39(11), 1785-1798. https://doi.org/10.1093/ndt/gfae184
Vancouver
Barbir EB, Kitchlu A, Herrmann SM. Immune checkpoint inhibitor–associated nephritis—treatment standard. Nephrology Dialysis Transplantation. 2024;39(11):1785-1798. doi:10.1093/ndt/gfae184
BibTeX
@article{Barbir2024,
author = {Barbir, Elena-Bianca and Kitchlu, Abhijat and Herrmann, Sandra M},
title = {Immune checkpoint inhibitor–associated nephritis—treatment standard},
journal = {Nephrology Dialysis Transplantation},
year = {2024},
volume = {39},
number = {11},
pages = {1785--1798},
doi = {10.1093/ndt/gfae184}
}
EUVIMED